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Purpose: To investigate the effects of mycophenolate mofetil (MMF) on proliferation and mucin-5AC (MUC5AC) mRNA
expression of normal human conjunctival goblet cells (CGCs) in vitro and to understand mechanisms of MMF in treatment
of dry eye syndrome at molecular level.
Methods: Purified human CGCs were treated with a series of graded concentrations of MMF after being confirmed by
immunocytochemistry and flow cytometry. Proliferation and MUC5AC mRNA expression of CGCs were measured by
Cell Count Kit-8 (CCK-8) and quantitative nested real-time reverse transcription polymerase chain reaction (QNRT-PCR
at 24 h after treatment. The cell proliferation and MUC5AC mRNA expressiion were compared among different doses of
MMF.
Results: MMF induced a dose-dependent upregulation of MUC5AC mRNA expression (F=238.851, p<0.01) but a biphase
effect on proliferation of the CGCs over 24 h of co-incubation. This biphase effect manifested as a dose-dependent increase
in cell numbers with MMF from 0.25 to 2.5 ng/ml, an unchanged population of the cells from 2.5 to 10 ng/ml and a reduced
population of the cells from 25 to 100 ng/ml.
Conclusions: MMF exerts biphase effects on cell regeneration and upregulates MUC5AC mRNA expression in CGCs in
vitro. It appears that the use of MMF at low concentrations is attractive in dry eye (DE) treatment.
Conjunctival  goblet  cells  (CGCs)  are  essential  for
maintaining the integrity of the ocular surface. As highly
specialized epithelial cells, CGCs are capable of producing
multiple  mucin  proteins  among  which,  Mucin-5AC
(MUC5AC) is a high-molecular-weight glycoprotein and the
major component of the mucous layer of the tear film. As an
essential component of tear film, it acts as a barrier to protect
the  ocular  surface  from  noxious  stimulation  and  helps
maintain the stability of tear film [1-4]. Because tear film
instability is considered to be one of the key factors of dry eye
(DE), CGCs and MUC5AC have drawn wide attention in DE
studies.  Impression  cytology  shows  that  patients  with
moderate to severe DE have a decreased number of CGCs.
Conjunctival  MUC5AC  deficiency  is  also  present  in  DE
patients, and is associated with Sjogren syndrome (SS) and
Stevens-Johnson syndrome [5-7].
It is now recognized that inflammation plays a key role
in the pathogenesis of DE [8,9]. In animal models, DE is
associated with T- and B-cell mediated inflammation [10,
11]. In I kappa B zata gene-disrupted mice, infiltration of
CD45R/B220(+) B and CD4(+) T cells in the ocular surface
is usually associated with a reduced number of goblet cells
[12,13].  The  population  of  T  and  B  cells  with  the  pro-
inflammatory cytokines increases in the lacrimal functional
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unit  (LFU)  of  DE  patients  [8,10,14-17].  CGCs  can  be
damaged by an activated inflammatory cascade. Both B and
T cells migrate into LFU, produce inflammatory cytokines
(such  as  IFN-γto)  and  therefore  enhance  the  immune
responses as evidenced by an increase in adhesion molecules
produced by conjunctival tissue. Thus, interruption of such an
inflammatory cascade by suppressing the activities of B and
T cells maybe effective in protecting CGCs.
A variety of dry eye treatments have been focused on
restoring the normal tear film, repairing damage of the ocular
surface,  and  relieving  the  symptoms.  Immunosuppressive
agents have been widely investigated because they are capable
of  inhibiting  the  vicious  circle  of  inflammation  in  DE.
Cyclosporine  A  (CsA),  an  inhibitor  of  T  cells,  has  been
approved by the Food and Drug Administration for use in the
treatment of the DE condition in humans [6,18]. Topical CsA
is effective clinically, but still in limited use due to side effects
such as eye hyperemia, stinging, burning, and transient blur
vision  [19].  Therefore,  a  clinically  acceptable
immunosuppressive should be effective with minimal side
effects.
Mycophenolate mofetil (MMF) is an inhibitor to T and B
lymphocytes, which has been reported to be effective in the
treatment of transplant rejection and multiple autoimmune
diseases.  Unlike  CsA,  MMF  does  not  interfere  with  IL-2
pathways. It suppresses the immunosuppressive system by
reversibly  inhibiting  inosine-5-monophosphate
dehydrogenase in the purine synthesis pathway [20]. Previous
studies  have  reported  that  MMF  is  effective  and  safe  in
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1913prolonging  the  survival  of  corneal  transplants  and  in  the
treatment  of  ocular  inflammation  diseases.  In  addition,
evidence  also  suggests  two  main  superiorities  of  MMF
compared with other immunosuppressive drugs, such as CsA:
1. lower side effects and better tolerability, and 2. a synergistic
effect  with  other  immunosuppressive  drugs  and
corticosteroids [21-26]. Theoretically, MMF may be a potent
immunosuppressive agent in the management of DE.
This study investigated effects of MMF on in vitro growth
of human CGCs to understand the molecular mechanisms of
MMF in the treatment of dry eye syndrome.
METHODS
Isolation and culture of CGCs: Human CGCs were isolated
as  described  previously  [4].  In  brief,  normal  human
conjunctival  tissues  were  obtained  from  patients  who
underwent periocular surgery after informed consent at the
Zhongshan Ophthalmic Center. The procedure followed the
ethical guidelines of the Declaration of Helsinki. Surgically
excised tissues were immediately placed in D-Hanks solution
consisting of 300 μg/ml penicillin-streptomycin. Three to four
minced tissues explants were placed into one well of a six-
well plate pre-coated with fetal bovine serum, and kept in a
humidified incubator (95% air and 5% CO2 at 37 °C) for 15
min. Adherent explants were fed every two days with RPMI
1640 medium supplemented with 10% fetal bovine serum
(FBS),  2  mM  glutamine,  and  100  μg/ml  penicillin-
streptomycin,  and  grown  under  routine  culture  conditions
(95% air and 5% CO2 at 37 °C). After 3–5 days, the tissue
explants were removed to avoid contamination by nongoblet
cells. If even one tissue explant displayed connective tissue
morphology, the whole well was discarded. Nongoblet cells
were discarded using a conventional plastic cell scraper. A
further purification was performed by enzymatic digestion
method. Two to five passage goblet cells (purity over 98.00%)
were used in all experiments.
Immunocytochemistry: The cultured cells were examined for
the presence of cytokeratins 4 and 7 (CK-4, CK-7)and for
MUC5AC.  Passage  cells  were  seeded  on  coverslips  at  a
density of 1×104 and incubated at 37 °C in humid atmosphere
of 5% CO2/95% O2. After three days, confluent CGCs were
fixed with 4% paraformaldehyde for 15 min, washed with
PBS three times, permeabilized in 1% Triton X-100 for 20
min, washed three times, and blocked with 1% BSA for 30
min. Then, fixed and permeabilized cells were incubated with
the  following  primary  antibodies:  mouse  anti-human
cytokeratin 7 (1:200 in PBS; Abcam, Cambridge, UK), rabbit
anti-human MUC5AC (1:100 in PBS; Abcam), and mouse
anti-human  cytokeratin  4  (1:200  in  PBS;  Abcam).  The
secondary antibodies were fluorescein isothiocyanate (FITC)-
and  tetramethylrhodamine  isothiocyanate-conjugated  anti-
mouse and anti-rabbit antibodies (1:50 in PBS; Abcam). The
primary antibodies were incubated for 1 h at room temperature
after  being  maintained  overnight  at  4  °C.  The  second
antibodies  were  incubated  for  2  h  at  room  temperature.
Negative  control  staining  was  performed  by  omitting  the
primary antibodies. The cells were viewed with a confocal
microscope (Carl Zeiss, Gottingen, Germany).
Flow cytometry analysis of the purity of the CGCs in culture:
The  percentage  of  cells  found  to  be  immunoreactive  for
cytokeratin 7 (CK-7), a specific marker of goblet cells, was
evaluated using flow cytometry with an Elite flow cytometer
(Beckman-Coulter, Brea, CA). Briefly, purified cells were
pretreated with the Fix & Perm cell permeabilization buffer
(eBioscience,  San  Diego,  CA).  The  monoclonal  antibody
against CK-7 (1:100 in PBS; Abcam) was incubated at 4 °C
for 30 min. The FITC-labeled second antibody (1:200 in PBS;
Caltag, Fremont, CA) was incubated at 4 °C for 30 min while
protected from light.
In vitro proliferation assays: Cell proliferation assays were
performed using a Cell Counting Kit-8 (CCK-8; Donjindo,
Kumamoto,  Japan)  according  to  the  manufacturer’s
TABLE 1. SEQUENCES OF PRIMER AND TAQMAN PROBES FOR PCR ASSAYS.
Object Type       Sequence
QNRT–PCR assay
First-step PCR outer forward primer                      5′-TGACGGACCTGGATGTGGT-3′
  outer reverse primer                       5′-TGTCATTCCCGTAGCAGTAGGA-3′
Second-step PCR TaqMan forward primer                 5′-TGCGTCCCACGACATCTG-3′
  TaqMan reverse primer                  5′-CAGGTGAATGGGCACATGTG-3
  TaqMan probe-mutation-FAM       5′-FAM-ATCGATTGGAGAGGCCGGACCG-TAMRA-3′
Internal control Human-β-actin forward primer        5′-GCATGGGTCAGAAGGATTCCT-3′
 
Human-β-actin reverse primer       5′-TCGTCCCAGTTGGTGACGAT-3′
 
TaqMan probe-mutation-FAM       5′-FAM-CCTCACCCTGAAGTACCCCATCGAGC-TAMRA-3′
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1914instructions. Purified CGCs (1×105/well) were cultured in
flat-bottom 96-well microtiter plates with the plating medium.
One day later, the medium was refed with the growth medium
containing the MMF (Roche, Mannheim, Germany), or the
growth  medium  without  agent  (control  group).  The
concentrations of MMF in the medium ranged from 0.25 to
100 ng/ml. After 24 h, the cells in each well were measured
as  the  absorbance  (450  nm).  All  measurements  were
performed in sextuplicate. Results were expressesd as mean
of  A450±SD.  The  percent  of  CGCs  proliferation  was
calculated as follows: proliferating cell (%)=[(Ae-Ab)/(Ac-
Ab)]*100%, where Ae, Ab and Ac are A450 of experimental,
blank and control group, respectively.
Quantitative  nested  real-time  reverse  transcription
polymerase chain reaction (QNRT–PCR):
Total RNA isolation and cDNA synthesis—Purified
cells were seeded in 12-well plates with the growth medium,
and grew to 75% confluence. Cells were stimulated without
(control) or with MMF (0.25 ng/ml, 2.5 ng/ml, and 25 ng/ml),
and incubated for 24 h. For RNA extraction, 1 ml Trizol
(Invitrogen, Carlsbad, CA) were added to CGCs sample, and
were  then  gradually  processed  using  0.2  ml  chloroform
(Sigma-Aldrich, St. Louis, MO) and avantin (Sigma-Aldrich).
After  centrifugation,  supernatant  was  removed.  Extracted
RNA  pellet  was  then  washed  with  75%  ethanol  (Sigma-
Aldrich) and centrifuged at 7,500 r/min for 5 min at 4 °C. After
vacuum desiccation (5–10 min), the extracted RNA specimen
was resuspended in diethyl pyrocarbonate- (DEPC) treated
water and then stored at −80 °C until it was used. Reverse
transcription of RNA was performed with ABI Geneamp 9700
PCR systems (Applied Biosystems, Foster City, CA) with
cDNA synthesized from 4 μg of total RNA.
Two  steps  of  quantitative  nested  real-time
transcription polymerase chain reaction (QNRT-PCR)—
QNRT–PCR consists of two consecutive PCR amplification
steps. In the first step, a 10 μl mixture of the PCR solution
containing 10 mM Tris-HCl (pH 8.0), 50 mM KCl, 1.5 mM
MgCl2, 10 mM each of deoxynucleoside triphosphate mixture,
3 U of Taq DNA polymerase, and 10 pM (each) of the outer
forward or reverse primers were prepared. Four μl of the
cDNA specimen as the template was amplified by using the
outer forward (F-1) or reverse (R-1) primer, under the same
assay conditions as in the conventional single PCR (Table 1
and Table 2). For the second step, a pair of inner primers for
MUC5AC (TaqMan forward primer [TqMn-F] and TaqMan
reverse  primer  [TqMn-R])  were  prepared  (Table  1).  In
addition, two specific TaqMan probes, which were labeled
with  the  fluorescent  reporter  dye  6-carboxyfluorescein
(FAM), were prepared (Table 1). As the template, 5 μl of the
first step PCR product at the second step was added to the PCR
solution mixture (each total reaction volume was 50 μl). This
preparation was subjected to the protocol shown in Table 2,
and the procedure used the ABI Geneamp 9700 PCR system
(Applied Biosystems).
RESULTS
Characterization  and  purity  of  CGCs  in  culture:  Double
immunolabeling  (CK-7  and  MUC5AC)  and  confocal
microscopy analysis were used to identify cultured CGCs. It
was found that passaged cells stained intensely for CK-7 and
MUC5AC, which were well established to be specific markers
of  CGCs,  while  they  did  not  stain  for  CK-4.  CK-7  and
MUC5AC often colocalized in the same passaged cell (Figure
1). CK-7, as an intermediate filament, was located in the
cytoplasm. MUC5AC, located within the secretory granules,
was shown under punctate staining. To further evaluate the
purity of purified cells, flow cytometry was used. The purity
of CGCs, shown as the percentage of CK-7(+) cells, was
indicated to be over 98.06% (Figure 2).
Effect of MMF on proliferation of human CGCs in culture:
MMF exerted biphase effects on the proliferation of human
CGCs (Figure 3). After intervention with MMF for 24 h, it
was shown that MMF, within the range of 0.25 ng/ml-1 ng/
ml,  significantly  increased  CGC  proliferation  (p<0.01).
However, at higher concentrations (25 ng/ml, 50 ng/ml, and
100 ng/ml), MMF decreased CGCs proliferation (p<0.01). In
addition, CCK-8 also showed that MMF (2.5 ng/ml, 50 ng/ml,
and 10 ng/ml) had no effect on the proliferation of CGCs
(p>0.01). The lowest concentrations required to promote and/
or inhibit cell viability were 0.25 ng/ml and/or 25 ng/ml,
respectively, while the lowest concentration of MMF to have
no cytotoxic effect was 2.5 ng/ml.
Figure  1.  Photomicrographs  of  CGCs  in  vitro.  Double
immunolabeling for CK-7 and MUC5AC indicate the presence of
CK-7 (shown in green) and MUC5AC (shown in red) in the same
cell in culture. The scale bar represents 20 μm.
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1915MMF increases MUC5AC mRNA expression in human CGCs
in culture: MMF significantly increased MUC5AC mRNA
expression  (Figure  4)  in  a  dose  dependent  manner.  At
concentrations of 0.25, 2.5, and 25 ng/ml, MMF significantly
increased MUC5AC mRNA expression by 2.3±0.5, 3.8±0.8,
and 43.9±2.6 times more than the control group respectively
(p<0.01).  The  main  peak  of  expression  appears  at  the
concentration of 25 ng/ml.
DISCUSSION
In this present study, MMF demonstrates a biphase effect on
CGCs proliferation and an upregulation of MUC5AC mRNA
expression, suggesting that an optimal dose is one of the
important factors determining the effectiveness in clinical use
Figure 2. Flow cytometry analysis of CK-7 expression. A: negative
control. B: with antibody against CK-7. Numenator histogram gated
events: 9,806. Denominator histogram gated events: 10,000% Gated:
98.06%.
of  MMF.  Dry  eye  syndrome  is  an  inflammatory  process
triggered by multiple factors and inhibition of this process is
critical to relieve the symptoms and signs for DE patients.
Since both T and B cells are involved in the inflammatory
process of DE, MMF which is an inhibitor for T and B cells
with relatively mild adverse responses has been investigated
as a potential agent for treatment of DE patients. Interestingly,
a enhancing effect of MMF on proliferation of CGCs at lower
concentrations is demonstrated in this present study. At a dose
of 0.25, 0.5 and 1 ng/ml, MMF increases cell viability by
15.6%, 13%, and 20.6%, respectively, when compared to the
control group. As the number and integrity of goblet cells are
associated with the outcome of DE, the capability of MMF in
stimulating  proliferation  of  CGCs  may  provide  a  better
alternative to current DE therapies if it is proven in vivo
studies. A dose of MMF at 100, 50 or 25 ng/ml for 24 h can
reduce cell viability by 49.7%, 36.3% or 19.6%, respectively,
compared to the control group. This finding is consistent with
studies  using  MMF  (5–50  ng/ml)  on  other  cells  such  as
Figure 3. Biphase effects of MMF on proliferation in CGCs in vitro.
CGCs were incubated for 24 h with increasing concentrations of
MMF. Three independent experiments were analyzed by CCK-8, and
means±SD  are  shown  in  the  graph.  *p<0.01  versus  control  by
ANOVA.
TABLE 2. PCR ASSAY CONDITIONS.
  Value
PCR assay conditions First-step PCR Second-step PCR
QNRT–PCR
Initial denature 93.0 °C, 5 min  
Amplification
Denature 93.0 °C, 30 s  
Annealing 55.0 °C, 45 s  
Extension 72.0 °C, 45 s  
Final extension 72.0 °C, 7 min  
Incubation   93.0 °C, 3 min
Initial denature   95.0 °C, 10 min
Amplification
Denature   93.0 °C, 30 s
Annealing-extension   55.0 °C, 45 s
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1916lymphocytes,  monocytes,  vascular  smooth  muscle  cells,
fibroblasts,  and  human  intrahepatic  biliary  epithelial  cells
[20,27-30].
Previous  studies  confirm  that  the  cytostatic  effect  of
MMF on lymphocytes is to deplet intracellular guanosine
nucleosides  by  reversibly  inhibiting  inosione-5-
monophosphate  dehydrogenase  (IMPDH)  in  the  de  novo
purine synthesis pathway [20,31-34]. However, mechanisms
of MMF involved in the proliferation-enhancement of cells
are  not  clear.  In  general,  there  are  two  pathways  for
biosynthesis of purine in cells – the de novo pathway and the
salvage pathway. Goblet cells of the eye may rely on these
two pathways to form purines for synthesis of DNA and RNA
of the cells. Since IMPDH is not involved in the salvage
pathway, the proliferation enhancing effect may be due to the
increased  purine  synthesis  by  the  salvage  pathway  to
compensate absence of the de novo pathway. Goblet cells,
which synthesize and secretes MUC5AC, are located not only
in conjunctiva but also in other epithelial tissues. Little is
known about the genes associated with MUC5AC production
in CGCs, however, SAM-pointed domain–containing Ets-like
factor (SPDEF) has been demonstrated to be the key genetic
switch in pulmonary and intestinal goblet cells. It has been
shown  that  SPDEF  can  induce  mRNA  expression  of
MUC5AC in progenitors of goblet cells with no associated
proliferation of goblet cells [35] in the respiratory tract, known
as the progenitors of goblet cells. This result is similar to a
mismatch  between  MUC5AC  mRNA  expression  and
proliferation of the associated CGCs under treatment with
higher  concentrations  of  MMF  in  the  present  study.  This
mismatch indicates that an increased secretion of mucin in tear
film could be due to an enhanced function of the individual
CGCs rather than the increased number of the cells.
The minimum effective concentration (MEC) of MMF in
the control of auto-immune response for DE has been included
in  the  concentrations  used  in  the  present  study  based  on
previous in vitro and in vivo studies [36,37]. In addition, the
Figure 4. Enhancing effect of MUC5AC mRNA expression in CGCs
in vitro after 24 h exposure to increasing concentrations of MMF.
Three independent experiments were analyzed by QNRT–PCR, and
means±SD  are  shown  in  the  graph.  *p<0.01  versus  control  by
ANOVA.
doses of MMF used in this present study are similar to those
currently recommended in the Spare-the-Nephron trial where
patients  were  treated  with  MMF  and  sirolimus  (an
immunosuppressive  drug  produced  by  the  actinomycete
Streptomyces hygroscopicus) [37]. In the Spare-the-Nephron
trial, an oral dose (1–1.5 g/kg) of MMF twice daily produces
a plasma concentration varying from 5 to 10 ng/ml which can
effectively suppress the lympholeukocytes. Therefore, MMF
at doses from 0.5 ng.ml to 10 ng/ml in the present study are
expected to effectively inhibit the lymphocytes involved in
the inflammation of DE, in addition to its protential to enhance
the protective role of the CGCs. Furthermore, MMF at 0.25
to 0.5 ng/ml appears to be the optimal dose in the treatment
of DE with respect to the characteristics of minimum effective
dose, great human CGCs proliferation enhancing effect, and
significant  upregulation  of  MUC5AC  mRNA  expression.
However, whether MMF can suppress the immune system and
provide protective therapy for dry eye patients at this range of
doses still needs to be investigated in vivo.
In conclusion, this study demonstrates that MMF exerts
biphase effects on proliferation and upregulates MUC5AC
mRNA expression of CGCs. It appears that MMF adjusted at
an optimal concentration has a potential effect to control the
inflammation and enhance the function of goblet cells for
patients having dry eye syndrome.
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